Immunophenotyping as a guide for targeted therapy

Bailliere's Best Practice and Research in Clinical Haematology

Volumn 16, Issue 4, 2003, Pages 629-644

  Sonneveld, Pieter ^a   Pieters, Rob ^b  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

Author keywords

Acute lymphoblastic leukemia; Acute myeloid leukemia; Anti CD33; Antibody; BCRP; Flt3 inhibitor; Immunotherapy; LRP; MRP; Multidrug resistance; Mylotarg; P gp

Indexed keywords

ABC TRANSPORTER; ALKYLATING AGENT; AMSACRINE; ANTHRACYCLINE; ANTIMETABOLITE; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DAUNORUBICIN; DIFFERENTIATION ANTIGEN; DOCETAXEL; DOXORUBICIN; EPIPODOPHYLLOTOXIN; ETOPOSIDE; GEMTUZUMAB OZOGAMICIN; GLYCOPROTEIN P; IDARUBICIN; IMATINIB; MELPHALAN; MULTIDRUG RESISTANCE PROTEIN; PACLITAXEL; PLATINUM DERIVATIVE; PROTEIN INHIBITOR; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; TENIPOSIDE; UNINDEXED DRUG; VINBLASTINE; VINCA ALKALOID; VINCRISTINE; 4 [6 METHOXY 7 [3 (1 PIPERIDINYL)PROPOXY] 4 QUINAZOLINYL] 1 PIPERAZINECARBOXYLIC ACID (4 ISOPROPOXYPHENYL)AMIDE; 6,7 DIMETHOXY 2 PHENYLQUINOXALINE; BIRICODAR; BREAST CANCER RESISTANCE PROTEIN; CEP 701; CYCLOSPORIN A; ELACRIDAR; FLT3 LIGAND; LUNG RESISTANCE PROTEIN; MIDOSTAURIN; MITOXANTRONE; SEMAXANIB; VALSPODAR; VASCULOTROPIN RECEPTOR 1; VERAPAMIL; ZOSUQUIDAR;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; ANTIGEN EXPRESSION; ANTIGEN SPECIFICITY; CANCER CLASSIFICATION; CANCER RECURRENCE; CELL LINEAGE; CHRONIC LEUKEMIA; CROSS RESISTANCE; DRUG ACTIVITY; DRUG MECHANISM; DRUG RESPONSE; DRUG TARGETING; HUMAN; IMMUNOPHENOTYPING; LEUKEMIA; LEUKEMIA CELL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REVIEW; CANCER THERAPY; CHEMOTHERAPY; CLINICAL TRIAL; DISEASE CLASSIFICATION; IMMUNOTHERAPY; TREATMENT OUTCOME;

EID: 0242521475     PISSN: 15216926     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1521-6926(03)00066-5     Document Type: Article

References (143)

1. Fojo AT, Whang-Peng J, Gottesmann MM & Pastan I. Amplification of DNA sequences in human multidrug-resistant KB carcinoma cells. Proceedings of the National Academy of Sciences of the USA 1985; 82: 7661-7665.
2. Lemontt JF, Azzaria M & Gros P. Increased mdr gene expression and decreased drug accumulation in multidrug-resistant human melanoma cells. Cancer Research 1988; 48: 6348-6353.
3. Linenberger ML, Hong T, Flowers D et al. Multidrug-resistance phenotype and clinical responses to gemtuzumab ozogamicin. Blood 2001; 98: 988-994.
4. Hrycyna CA, Zhang S, Ramachandra M, et al. Functional and molecular characterization of the human multidrug transporter. In Gupta S & Tsuruo T (eds) Multidrug Resistance in Cancer. Chicester: Wiley, 1996. p. 29.
5. Chen CJ, Chin JE, Ueda K et al. Internal duplication and homology with bacterial transport proteins in the MDR1 (P-glycoprotein) gene from multidrug resistance cells. Cell 1986; 47: 381-389.
6. Germann UA. P-glycoprotein - a mediator of multidrug resistance in tumour cells. European Journal of Cancer 1996; 32A: 927-944.
7. Goodfellow HR, Sardini A, Ruetz S et al. Protein kinase C-mediated phosphorylation does not regulate drug transport by the human multidrug resistance P-glycoprotein. Journal of Biological Chemistry 1996; 271: 13668-13674.
8. Schinkel AH, Kemp S, Dolle M et al. N-Glycosylation and deletion mutants of the human MDR1 P-glycoprotein. Journal of Biological Chemistry 1993; 268: 7474-7481.
9. Schinkel AH & Jonker JW. Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview. Advances in Drug Delivery 2003; 55: 3-29.
10. Yague E, Armesilla AL, Harrison G et al. P-glycoprotein (MDR1) expression in leukemic cells is regulated at two distinct steps: mRNA stabilization and translational initiation. Journal of Biological Chemistry 2003; 278: 10344-10352.
11. Bolhuis H, van Veen HW, Molenaar D et al. Multidrug resistance in Lactococcus lactis: evidence for ATP-dependent drug extrusion from the inner leaflet of the cytoplasmic membrane. EMBO Journal 1996; 15: 4239-4245.
12. Smit JJM, Schinkel AH, Oude Elferink RPJ et al. Homozygous disruption of of the murine mdr2 P-glycoprotein gene leads to a complete absence of phospholipid from bile and to liver disease. Cell 1993; 75: 451-462.
13. Smith AJ, Timmermans-Herweijgers JLPM, Roelofsen B et al. The human MDR3 P-glycoprotein promotes translocation of phosphatidylcholine through the plasma membrane of fibroblasts from transgenic mice. FEBS Letters 1994; 354: 263-266.
14. Smith AJ, de Vree JM, Ottenhof R et al. Hepatocyte-specific expression of the huamn MDR3 P-glycoprotein gene restores the biliary phosphatidylcholine excretion absent in mdr2 (-/-) mice. Hepatology 1998; 28: 530-536.
15. Helvoort van A, Smith AJ, Sprong H et al. MDR1 P-glycoprotein is a lipid translocase of broad specificity, while MDR3 P-glycoprotein specifically translocates phosphatidylcholine. Cell 1996; 87: 507-517.
16. Sonneveld P & List AF. Chemotherapy resistance in acute myeloid leukemia. In Baillière's Clinical Haematology 2001; 14: 211-223.
17. Beck WT, Grogan TM, Willman CL et al. Methods to detect P-glycoprotein-associated multidrug resistance in patients' tumors: consensus recommendations. Cancer Research 1996; 56: 3010-3020.
18. Broxterman HJ, Sonneveld P, Feller N et al. Quality control of multidrug resistance assays in adult acute leukemia: correlation between assays for P-glycoprotein expression and activity. Blood 1996; 87: 4809-4816.
19. Campos L, Guyotat D, Archimbaud E et al. Clinical significance of multidrug resistance P-glycoprotein expression on acute non-lymphoblastic leukemia cells at diagnosis. Blood 1992; 79: 473-476.
20. Del Poeta G, Stasi R, Aronica G et al. Clinical relevance of P-glycoprotein expression in de novo acute myeloid leukemia. Blood 1996; 87: 1997-2004.
21. Leith CP, Kopecky KJ, Goldwin J et al. Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy: a Southwest Oncology Group study. Blood 1997; 89: 3323-3329.
22. Leith CP, Kopecky KJ & Chen IM. Frequency and clinical significance of the expression of multi drug resistance proteins MDR1/P-gp, MRP1, and LRP in acute myeloid leukemia. A Southwest Oncology Group Study. Blood 1999; 94: 1086-1099.
23. van den Heuvel-Eibrink MM, van der Holt B, te Boekhorst PA et al. MDR1 expression is an independent prognostic factor for response and survival in de novo acute myeloid leukaemia. British Journal of Haematology 1997; 99: 76-83.
24. Cole SPC, Bhardwaj G, Gerlach JH et al. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 1992; 258: 1650-1654.
25. Jedlitschlky C, Leier I, Buchholz U et al. Transport of glutathione, glucuronate, and sulfate conjugates by the MRP gene-encoded conjugate export pump. Cancer Research 1996; 56: 988-994.
26. Kool M, de Haas M, Scheffer GL et al. Analysis of expression of cMOAT (MPR2) MPR3, MRP4, and MPR 5, homologues of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines. Cancer Research 1997; 57: 3537-3547.
27. + peripheral blood cells. Clinical Cancer Research 1998; 4: 1727-1736.
28. van der Kolk DM, Vellenga E, van der Veen AY et al. Deletion of the multidrug resistance protein MRP1 gene in acute myeloid leukemia: the impact on MRP activity. Blood 2000; 95: 3514-3518.
29. Flens MJ, Zaman GJR, van der Valk P et al. Tissue distribution of the multidrug resistance protein. American Journal of Pathology 1996; 148: 1237-1247.
30. Den Boer ML, Zwaan CM & Pieters R. Optimal immunocytochemical and flow cytometric detection of P-gp, MRP and LPR in childhood acute lymphoblastic leukemia. Leukemia 1997; 11: 1078-1085.
31. Zhou DC, Ramond S, Viguie F et al. Sequential emergence of MRP- en MDR1-gene over-expression as well as MDR1-gene translocation in homoharringtonine selected K562 human leukemia cell lines. International Journal of Cancer 1996; 65: 365-371.
32. van der Kolk DM, de Vries EGE, Noordhoek L et al. Activity and expression of the multidrug resistance proteins P-glycoprotein, MRP1, MRP2, MRP3, and MRP5 in de novo and relapsed acute myeloid leukemia. Leukemia 2001; 5: 1544-1550.
33. Schneider E, Cowan KH, Bader H et al. Increased expression of the multidrug resistance-associated protein gene in relapsed leukemia. Blood 1995; 85: 186-190.
34. Maliepaard M, van Gastelen MA, de Jong LA et al. Overexpression of the BCRP/MXR/ABCP gene in a topotecan selected ovarian tumor cell line. Cancer Research 1999; 59: 4559-4563.
35. Doyle LA, Yang W, Abruzzo LV et al. A multidrug resistance transporter from human MCF-7 breast cancer cells (published erratum appears in Proceedings of the National Academy of Sciences of the USA 1999; 96:2569). Proceedings of the National Academy of Sciences of the USA 1998; 95: 15 665-15 670.
36. Ross DD, Yang W, Abruzzo LV et al. A typical multidrug resistance: breast cancer resistance protein messenger RNA expression in mitoxantrone-selected cell lines. Journal of the National Cancer Institute 1999; 91: 429-433.
37. Miyake K, Mickley L, Litman T et al. Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone-resistant cells; demonstration of homology to ABC transport genes. Cancer Research 1999; 59: 8-13.
38. De Bruin M, Miyake K, Litman T et al. Reversal of resistance by GF120918 in cell lines expressing the ABC halftransporter, MXR. Cancer Letters 1999; 146: 117-126.
39. Allikmets R, Schriml LM, Hutchinson A et al. Human placenta-specific ATP-binding casette gene (ABCP) on chromosome 4q22 that is involted in multidrug resistance. Cancer Research 1998; 58: 5337-5339.
40. Ross DD. Novel mechanisms of drug resistance in leukemia. Leukemia 2000; 14: 467-473.
41. van den Heuvel-Eibrink MM, Wiemer EAC, Prins A et al. Increased expression of the breast cancer resistance protein (BCRP) in relapsed or refractory acute myeloid leukemia (AML). Leukemia 2002; 16: 833-839.
42. Ross DD, Karp JE, Chen TT & Doyle LA. Expression of breast cancer resistance protein in blast cells from patients with acute leukemia. Blood 2000; 96: 365-368.
43. Robey RW, Honjo Y, van de Laar A et al. A functional assay for detection of the mitoxantrone resistance protein, MXR(ABCG2). Biochimica et Biophysica Acta 2001; 1512: 1714-1782.
44. Scheffer GL, Wijngaard PLJ, Flens MJ et al. The drug resistance related protein LRP is the human major vault protein. Nature Medicine 1995; 1: 578-582.
45. Kickhoefer VA, Rajavel KS, Scheffer GL et al. Vaults are up-regulated in multidrug-resistant cancer cell lines. Journal of Biological Chemistry 1998; 273: 8971-8974.
46. Izquierdo M, Scheffer G, Flens M et al. Broad distribution of the multidrug resistance-related vault lung protein in normal human tissues and tumors. American Journal of Pathology 1996; 148: 877-887.
47. List AF, Spier CS, Grogan TM et al. Overexpression of the major vault transporter protein lung resistance protein predicts treatment outcome in acute myeloid leukemia. Blood 1996; 87: 2464-2469.
48. Filipits M, Pohl G, Stranzl et al. Expression of the lung resistance protein predicts poor outcome in de novo acute myeloid leukemia. Blood 1998; 91: 1508-1513.
49. Pirker R, Pohl G & Stranzl T. Expression of the lung resistance protein (LRP) predicts poor outcome in de novo acute myeloid leukemia. Blood 1997; 90: 2519a.
50. Borg AG, Burgess P, Green LM et al. Overexpression of lung-resistance protein and increased P-glycoprotein function in acute myeloid leukemia cells predict a poor response to chemotherapy and reduced patient survival. British Journal of Haematology 1998; 103: 1083-1091.
51. Hart SM, Ganeshuuru K, Scheper RJ et al. Expression of the human major vault protein (LRP) in acute myeloid leukemia. Experimental Hematology 1997; 25: 1227-1232.
52. Legrand O, Simonin G, Zittoun R & Marie JP. Lung resistance protein (LRP) gene expression in adult acute myeloid leukemia: a critical evaluation by three techniques. Leukemia 1998; 12: 1367-1374.
53. Pallis M, Turzanski J, Wheatley K et al. Use of standardized flow-cytometric determinants of multidrug resistance to analyse response to remission induction chemotherapy in patients with acute myeloblastic leukemia. British Journal of Haematology 1999; 104: 258-265.
54. - cases. Blood 1995; 86: 2329-2342.
55. Kasimir-Bauer S, Ottinger H, Meusers P et al. In acute myeloid leukemia, co-expression of at least two proteins, including P-glycoprotein, the multidrug resistance-related protein, bcl-2, mutant p53 and the heat-shock protein 27, is predictive of the reponse to induction chemotherapy. Experimental Hematology 1998; 26: 1111-1117.
56. Michieli M, Damiani D, Ermacora A et al. P-glycoprotein(Pgp) and lung resistance-related protein (LRP) expression and function in leukaemic blast cells. British Journal of Haematology 1997; 96: 356-365.
57. Raaymakers HGP, Izquierdo MAI, Lokhorst HM et al. Lung-resistance protein expression is a negative predictive factor for response to alkylating chemotherapy and survival in multiple myeloma, and can be overcome by dose intensification. Blood 1997; 91: 1029-1036.
58. Mossink MH, van Zon, Fränzel-Luiten E et al. Disruption of the murine major vault protein (MVP/LRP) gene does not induce hypersensitivity to cytostatics. Cancer Research 2002; 62: 7298-7304.
59. Frey T, Yue S & Haugland RP. Dyes providing increased sensitivity in flow-cytometric dye-efflux assays for multidrug resistance. Cytometry 1995; 20: 218-227.
60. Hollo Z, Homolaya L, Davis CW & Sarkadi B. Calcein accumulation as a fluorometric functional assay of multidrug transporter. Biochimica et Biophysica Acta 1994; 1191: 384-388.
61. Krishan A, Sauerteig A, Andritsch I & Wellham L. Flow cytometric analysis of the multiple drug resistance phenotype. Leukemia 1997; 11: 1138-1146.
62. Krishan A. Monitoring of cellular resistance to cancer chemotherapy: drug retention and efflux. Methods in Cell Biology 2001; 64: 193-209.
63. Smith AJ, Mayer U, Schinkel AH & Borst P. Availability of PSC833, a substrate and inhibitor of P-glycoproteins, in various concentrations of serum. Journal of the National Cancer Institute 1998; 90: 1161-1166.
64. van Asperen J, van Tellingen O, Sparreboom A et al. Enhanced oral bioavailability of paclitaxel in mice treated with the P-glycoprotein blocker SDZ PSC 833. British Journal of Cancer 1997; 76: 1181-1183.
65. Starling JJ, Shepard RL, Cao J et al. Pharmacological characterization of LY335979: a potent cyclopropyidibenzosuberane modulator of P-glycoprotein. Advances in Enzyme Regulation 1997; 37: 335-347.
66. Germann UA, Ford PJ, Shlyakhter D et al. Chemosensitization and drug accumulation effects of VX-710, verapamil, cyclosporin A, MS-209 and GF120918 in multidrug resistant HL60/ADR cells expressing the multidrug resistance associated protein MRP. Anticancer Drugs 1997; 8: 141-155.
67. List AF, Spier C, Greer J et al. Phase I/II trial of cyclosporine as a chemotherapy resistance modifier in acute leukemia. Journal of Clinical Oncology 1993; 11: 1652.
68. Marie JP, Bastie JN, Coloma F et al. Cyclosporin A as a modifier agent in the salvage treatment of acute leukemia (AL). Leukemia 1993; 7: 821-824.
69. Tallman MS, Lee S, Sikic BI et al. Mitoxantrone, etoposide, and cytarabine plus cyclosporine for patients with relapsed or refractory acute myeloid leukemia: an Eastern Cooperative Oncology Group pilot study. Cancer 1999; 85: 358-367.
70. Advani R, Saba H, Rowe JM et al. Treatment of refractory/relapsed AML with chemotherapy plus the multidrug-resistance modulator PSC833 (Valspodar). Blood 1999; 93: 787-795.
71. Sonneveld P, Burnett A, Vossebeld P et al. Dose-finding study of valspodar (PSC833) with daunorubicin and cytarabine to reverse multidrug resistance in eldery patients with previously untreated acute myeloid leukemia. Hematolgy Journal 2000; 1: 421-441.
72. Baer M, George S, Dodge R et al. Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: CALGB study 9720. Blood 2002; 100: 1224-1232.
73. List AF, Kopecky KJ, Willman CL et al. Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study. Blood 2001; 98: 3212-3220.
74. Dorr R, Karanes C, Spier C et al. Phase I/II study of the P-glycoprotein modulator PSC 833 in patients with acute myeloid leukemia. Journal of Clinical Oncology 2001; 19: 1589-1599.
75. Chauncey TR, Rankin C, Anderson JE et al. A phase I study of induction chemotherapy for older patients with newly diagnosed acute myeloid leukemia (AML) using mitoxantron, etoposide, and the MDR modulator PSC 833: a southwest oncology group study 9617. Leukemia Research 2000; 24: 567-574.
76. Wattel E, Solary E, Hecquet B et al. Quinine improves the results of intensive chemotherapy in myelodysplastic syndromes expressing Pglycoprotein: results of a randomized study. British Journal of Haematology 1998; 102: 1015-1024.
77. Greenberg P, Advani R, Tallman M et al. Treatment of refractory/relapsed AML with PSC833 plus mitoxantrone, etoposide, cytarabine (PSC-MEC) vs MEC: randomized phase III trial (E2995). Blood 1999; 94: 510a.
78. Gilliland DG & Griffin JD. The roles of FLT3 in hematopoiesis and leukemia. Blood 2002; 100: 1532-1542.
79. Lyman SD. Biology of FLT3 ligand and receptor. International Journal of Hematology 1995; 62: 63-73.
80. Rosnet O, Buhring HJ, de Lapeyriere O et al. Expression and signal transduction of the FLT3 tyrosine kinase receptor. Acta Haematologica 1996; 95: 218-223.
81. Drexler HG. Expression of FLT3 receptor and response to FLT3 ligand by leukemic cells. Leukemia 1999; 10: 588-599.
82. Lisovsky M, Estrov Z, Zhang X et al. FLT3 ligand stimulates proliferation and inhibits apoptosis of acute myeloid leukemia cells: regulation of Bcl-2 and Bax. Blood 1996; 88: 3987-3997.
83. Turner AM, Lin NL, Issarachai S et al. FLT3 receptro expression on the surface of normal and malignant human hematopoietic cells. Blood 1996; 88: 3383-3390.
84. McKenna HJ, Smith FO, Brasel K et al. Effects of FLT3 ligand on acute mycloid and lymphagtic leukemic blast cells from children. Experimental Hematology 1996; 24: 378-385.
85. Birg F. Courcoul M, Rosnet O et al. Expression of the FMS/KIT-like gene FLT3 in human acute leukemias of the myeloid and lymphoid lineages. Blood 1992; 80: 2584-2593.
86. Carow CE, Levenstein M, Kaufmann SH et al. Expression of the hematopoietic growth factor receptor FLT3 (STK-I/Flk2) in human leukemias. Blood 1996; 87: 1089-1096.
87. Hawley TS, Fong AZ, Griesser H et al. Leukemic predisposition of mice transplanted with gene-modified hematopoietic precursors expression FLT3 ligand. Blood 1998; 92: 2003-2011.
88. Nakao M, Yokota S, Iwai T et al. Internal tandem duplication of the FLT3 gene found in acute myeloid leukemia. Leukemia 1918; 10: 1911-1911.
89. Hayakawa F, Towatari M, Kiyoi H, et al. Tandem-duplicated FLT3 constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell lines.
90. Kiyoi H, Towatari M, Yokota S et al. Internal tandem duplication of the FLT3 gene is a novel modality of elongation mutation which causes constitutive activation of the product. Leukemia 1998; 12: 1333-1337.
91. Kiyoi H, Ohno R, Ueda R et al. Mechanism of constitutive activation of FLT3 with internal tandem duplication in the juxtamembrane domain. Oncogene 2002; 21: 2555-2563.
92. Kelly LM, Yu JC, Boulton CL et al. CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML). Cancer Cell 2002; 1: 421-432.
93. Arrigoni P, Beretta C, Silvestri D et al. FLT3 internal tandem duplication in childhood acute myeloid leukemia: association with hyperleucocytosis in acute promyelocytic leukaemia. British Journal of Haematology 2003; 120: 89-92.
94. Noguera NI, Breccia M, Divona M et al. Alterations of the FLT3 gene in acute promyelocytic leukemia: association with diagnostic characteristics and analysis of clinical outcome in patients treated with the Italian AIDA protocol. Leukemia 2002; 16: 2185-2189.
95. Thiede C, Steudel C, Mohr B et al. Analysis of FLT3-activation mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood 2002; 99: 4326-4335.
96. Stirewalt DL, Kopecky KJ, Meshinchi S et al. FLT3 and RAS and TP53 mutations in elderly patients with acute myeloid leukemia. Blood 2001; 97: 3589-3595.
97. Kiyoi H, Naoe T, Yokota S et al. Internal tandem duplication of FLT3 associated with leukocytosis in acute promyelocytic leukemia. Leukemia Study Group of the Ministry of Health and Welfare (Kohseisho). Leukemia 1997; 11: 1447-1452.
98. Meshinchi S, Woods WG, Stirewalt DL et al. Prevalence and prognostic signiflcance of FLT3 internal tandem duplication in pediatric acute myeloid leukemia. Blood 2001; 97: 89-94.
99. Kottaridis PD, Gale RE, Frew ME et al. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood 2001; 98: 1752-1759.
100. Schnittger S, Schoch C, Dugas M et al. Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. Blood 2002; 100: 59-66.
101. Xu F, Taki T, Yang HW et al. Tandem duplication of the FLT3 gene is found in acute lymphoblastic leukaemia as well as acute myeloid leukaemia but not in myelodysplastic syndrome or juvenile chronic myelogenous leukaemia in children. British Journal of Haematology 1999; 105: 155-162.
102. Iwai T, Yokota S, Nakao M et al. Internal tandem duplication of FLT3 gene and clinical evaluation in childhood acute myeloid leukemia. The Children's Cancer and Leukemia Study Group, Japan. Leukemia 1999; 13: 38-43.
103. Kondo M, Horibe K, Takahashi Y et al. Prognostic value of internal tandem duplication of the FLT3 gene in childhood acute myelogenous leukemia. Med Ped Oncol 1999; 33: 525-529.
104. Xu F, Taki T, Eguchi M, et al. Tandem duplication of the FLT3 gene is infrequent in infant acute leukemia. Japan Infant Leukemia Study Group. Leukemia 200; 14: pp. 945-947.
105. Armstrong SA, Staunton JE, Silverman LB et al. MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia. Nature Genetics 2002; 30: 41-47.
106. Armstrong SA, Kung AL, Mabon ME et al. Inhibition of FLT3 in MLL. Validation of a therapeutic target identified by gene expression based classification. Cancer Cell 2003; 3: 173-183.
107. Abu-Duhier FM, Goodeve AC, Wilson GA et al. Identification of novel FLT-3 Asp 835 mutations in adult acute myeloid leukaemia. British Journal of Haematology 2001; 113: 983-988.
108. Yamamoto Y, Kiyoi H, Nakano Y et al. Activation mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood 2001; 97: 2434-2439.
109. Kainz B, Heintel D, zzmarculescu R et al. Jaeger Variable prognostic value of FLT3 internal tandem duplications in patients with de novo AML and a normal karyotype, t(15;17), t(8;21) or inv(16). Haematology Journal 2002; 3: 283-289.
110. Frohling S, Schlenk RF, Breitruck J. The AML Study Group Ulm et al. Acute myeloid leukemia. Blood 2002; 100: 4372-4380.
111. Moreno I, Martin G, Bolufer P et al. Incidence and prognostic value of FLT3 internal tandem duplication and D835 mutations in acute myeloid leukemia. Haematologica 2003; 88: 19-24.
112. Rombouts WJ, Blokland I, Lowenberg B & Ploemacher RE. Biological characteristics and prognosis of adult acute myeloid leukemia with internal tandem duplications in the FLT3 gene. Leukemia 2000; 14: 675-683.
113. Kiyoi H, Naoe T, Nakano Y et al. Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia. Blood 1999; 93: 3074-3080.
114. Whitman SP, Archer KJ, Feng L et al. Absence of the wild-ype allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a cancer and leukemia group B study. Cancer Research 2001; 61: 7233-7239.
115. Boissel N, Cayuela JM, Preudhomme C et al. Prognostic significance of FLT3 internal tandem repeat in patients with de novo acute myeloid leukemia treated with reinforced courses of chemotherapy. Leukemia 2002; 16: 1699-1704.
116. Naoe T, Kiyoe H, Yamamoto Y et al. FLT3 tyrosine kinase as a target molecule for selective antileukemic therapy. Cancer Chemotherapy and Pharmacology 2001; 48: S27-S30.
117. Tse KF, Allebach J, Levis M et al. Inhibition of the transforming activity of FLT3 internal tandem duplication mutants from AML patients by a tyrosine kinase inhibitor. Leukemia 2002; 16: 2027-2036.
118. Levis M, Tse KF, Smith BD et al. A FLT3 tyrosine kinase inhibitor is selectively cytotoxic to acute myeloid leukemia blasts harboring FLT3 internal tandem duplication mutations. Blood 2001; 98: 885-887.
119. Kelly LM, Liu Q, Kutok JL et al. FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model. Blood 2002; 99: 310-318.
120. Zheng R, Friedman AD & Small D. Targeted inhibition of FLT3 overcomes the block to myeloid differentiation in 32Dcl3 cells caused by expression of FLT3/ITD mutations. Blood 2002; 100: 4154-4161.
121. Levis M, Allebach J, Tse KF et al. A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo. Blood 2002; 99: 3885-3891.
122. Yee KW, O'Farrell AM, Smolich BD et al. SU5416 and SU5614 inhibit kinase activity of wild-type and mutant FLT3 receptor tyrosine kinase. Blood 2002; 100: 2941-2949.
123. O'Farrell AM, Abrams TJ, Yuen HA et al. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 2003; 101: 3597-3605.
124. Weisberg E, Boulton C, Kelly LM et al. Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412. Cancer Cell 2002; 1: 433-443.
125. Sawyers SL. Finding the next Gleevec: FLT3 targeted kinase inhibitor therapy for acute myeloid leukemia. Cancer Cell 2002; 1: 413-415.
126. Giles FJ, Stopeck AT, Silverman LR et al. SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes. Blood 2003.
127. Larson RA. Current use and future development of gemtuzumab ozogamicin. Seminars in Hematology 2001; 38: 24-31.
128. Giles FJ. Gemtuzumab ozogamicin: promise and challenge in patients with acute myeloid leukemia. Expert Reviews in Anticancer Therapy 2002; 2: 630-640.
129. Hinnman LM, Hamann PR, Wallace R et al. Preparation and characterization of monoclonal antibody conjugates of the calicheamicins: a novel and potent family of antitumor antibiotics. Cancer Research 1993; 53: 3336-3342.
130. van der Velden VH, Te Marvelde JG, Hoogeveen PG et al. Targeting of the CD33-calicheomicin immunoconjugate Mylotarg (CMA-676) in acute myeloid leukemia: in vivo and vitro saturation and internalization by leukemic and normal myeloid cells. Blood 2001; 97: 3197-3204.
131. + acute myeloid leukemia. Anticancer Drugs 2002; 13: 685-692.
132. Sievers EL, Appelbaum FR, Spielberger RT et al. Selection ablation of acute myeloid leukemia using antibody-targeted chemotherapy: a phase I study of an anti-CD33 calicheamicin immunoconjugate. Blood 1999; 93: 3678-3684.
133. Sievers EL, Larson RA, Stadtmauer EA et al. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33- positive acute myeloid leukemmia in first relapse. Journal of Clinical Oncology 2001; 19: 3244-3254.
134. Leopold LH, Berger MS & Feingold J. Acute and long-term toxicities associated with gemtuzumab ozogamicin (mylotarg®) therapy of acute myeloid leukemia. Clinics & Lymphoma 2002; 2: S29-S34.
135. Cohen AD, Luger SM, Sickles C et al. Gemtuzumab ozogamicin (Mylotarg) monotherapy for relapsed AML after hematopoietic stem cell transplant: efficacy and incidence of hepatic veno-occlusive disease. Bone Marrow Transplant 2002; 30: 23-28.
136. Rajvanshi P, Shulman HM, Sievers EL & McDonald GB. Hepatic sinusoidal obstruction after gemtuzumab ozogamicin (Mylotarg) therapy. Blood 2002; 99: 2310-2314.
137. Stadtmauer EA. Gemtuzumab ozogamicin in the treatment of acute myeloid leukemia. Current Oncology Reports 2002; 4: 375-380.
138. Lang K, Menzin J, Earle CC & Mallick R. Outcoms in patients treated with gemtuzumab ozogamicin for relapsed acute myelogenous leukemia. American Journal of Health Systems Pharmacology 2002; 59: 941-948.
139. Larson RA, Boogaerts M, Estey E et al. Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin). Leukemia 2002; 16: 1627-1639.
140. Berger MS, Leopold LH, Dowell JA et al. Licensure of gemtuzumab ozogamicin for the treatment of selected patients 60 years of age or older with acute myeloid leukemia in first relapse. Investigational New Drugs 2002; 20: 395-406.
141. Tsimberidou A, Estey E, Cortes J et al. Gemtuzumab, fludarabine,cytarabine and cyclosporine in patients with newly diagnosed acute myelogenous leukemia or high-risk myelodysplastic syndromes. Cancer 2003; 97: 1481-1487.
142. Alvarado Y, Tsimberidou A, Kantarjian H et al. Pilot study of Mylotarg, idarubicin and cytarabine combination regimen patients with primary resistant or relapsed acute myeloid leukemia. Cancer Chemotherapy and Pharmacology 2003; 51: 87-90.
143. Cortes J, Tsimberidou AM, Alvarez R et al. Mylotarg combined with topotecan and cytarabine in patients with refractory acute myelogenous leukemia. Cancer Chemotherapy and Pharmacology 2002; 50: 497-500.